Tuesday, May 23, 2023 – 11:00 – 11:30 am EST, 5:00 – 5:30 pm CET


Leveraging Advantages of Large Volume Subcutaneous Drug Delivery

The pharmaceutical industry continually faces the challenge of reducing time to market for new therapeutics. However, advancements in drug delivery technologies present promising opportunities to overcome these hurdles.

Innovative approaches in drug delivery systems, such as transitioning from intravenous (IV) to subcutaneous (SC) administration without significant formulation alterations and utilizing an original container closure have the potential to shorten development timelines, generate cost savings, and even extend dosing intervals.

In this 30-minute webinar, a drug delivery expert and executive CMC consultant will discuss how drug delivery innovative technologies like the enFuse® can improve speed-to-market.

This webinar is intended for Commercial, R&D, Combination Product Development leaders and CMC biopharmaceutical leaders.



Mehul Desai

PharmD, MBA
VP, Medical Affairs, Enable Injections


David Boisvert

Drug Delivery & Executive CMC Consultant


Matt Huddleston

EVP, Business Development & Chief Technology Officer, Enable Injections


Accelerate Time to Market – Leveraging Advantages of Large Volume Subcutaneous Drug Delivery

Live Webinar: Tuesday, May 23, 2023 – 11 – 11:30 am EST, 5-5:30 CET


Mehul Desai, PharmD, MBA – VP, Medical Affairs, Enable Injections

Mehul has vast experience in medical and clinical affairs across the pharmaceutical space. At Enable Injections, he leads medical and clinical programming to support publication, new partnerships, and regulatory approvals. Prior to Enable Injections, Mehul served as Associate Medical Director for argenx, driving the strategic direction, supporting clinical trial execution, and contributing to business development activities across various therapeutic areas. Previous experience includes field medical assignments in rare disease, nephrology and neurology for Mallinckrodt Pharmaceuticals, nephrology and hematology for Alexion Pharmaceuticals, and post-doctoral fellowship work in Medical Affairs for Johnson & Johnson.


David Boisvert, PhD, MBA – Drug Delivery & Executive CMC Consultant

David has been an executive-level CMC, technical operations, and manufacturing consultant since 2020, with more than 20 years of experience in drug and process development. He provides expertise in CMC drug substance and drug product process development, quality control support, stability program management, commercial manufacturing and planning, supply chain management, quality assurance support, root cause analysis, and risk assessments. Prior to consulting, David was the Vice President of Process Development, Manufacturing, and Supply Chain at Arch Oncology, with previous experience at Grifols, Portola Pharmaceuticals, Allergan and Bayer.


Matt Huddleston – EVP, Business Development, Chief Technology Officer, Enable Injections

Matt is an experienced medical device professional with more than 20 years of experience in startup environments with emphasis in project management, design, development, manufacturing, regulatory, and intellectual property. He has several issued and pending patents in the medical device field, including soft tissue and cardiovascular fixation devices and delivery instruments, histologic automated embedding systems, laparoscopic visualization devices, and automatic injection devices.